Myovant Sciences initiated at Goldman Sachs

Myovant Sciences initiated with a Neutral at Goldman Sachs. Goldman Sachs analyst Dana Flanders started Myovant Sciences with a Neutral rating and $25 price target. The analyst’s due diligence suggests a “likely slow build” for the antagonist class. Further, Flanders anticipates “minimal clinical differentiation” between the agents in development. The analyst views Myovant’s growth opportunity as attractive but sees competitive markets.
https://thefly.com/landingPageNews.php?id=2811527